# Johnson & Johnson's JNJ-6143 Shows 75% Response Rate in Early Trial

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/41172
Published: 2026-10-26T17:25:14.000Z
Updated: 2026-10-26T17:25:14.000Z
Section: Business

> The oral RIPTAC small molecule was previously known as HLD-0915.

Johnson & Johnson said its experimental oral drug JNJ-6143 produced a 75% tumor response rate in an early-stage trial involving people with advanced prostate cancer.

JNJ-6143 is a small molecule in the Regulated Induced Proximity Targeting Chimera (RIPTAC) class. The compound was previously known as HLD-0915.